Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
Active, not recruiting
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Drug: immunochemotherapies
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 220
- Registration Number
- NCT06170216
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy
Not Applicable
Not yet recruiting
- Conditions
- Pancreatic Tumor, BenignSolid Pseudopapillary Tumor of the PancreasPancreatic Neuroendocrine Tumor
- Interventions
- Procedure: Laparoscopic spleen-preserving distal pancreatectomy using the Kimura techniqueProcedure: Laparoscopic spleen-preserving distal pancreatectomy using the Warshaw technique
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 240
- Registration Number
- NCT06167421
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
Not yet recruiting
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 276
- Registration Number
- NCT06166147
- Locations
- 🇨🇳
Department of Hepato-Biliary-Pancreatic-Splenic Surgery, Shanghai General Hospital, Shanghai, Shanghai, China
🇨🇳Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
🇨🇳Department of General Sugery, Huadong Hospital, Shanghai, Shanghai, China
A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung Cancer
Completed
- Conditions
- Lung Cancer Non Small Cell
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 7067
- Registration Number
- NCT06161935
Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Therapy
Recruiting
- Conditions
- HER2-positive Breast Cancer
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT06161922
- Locations
- 🇨🇳
Keda Yu, Shanghai, China
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
Not Applicable
Recruiting
- Conditions
- Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
- Interventions
- Drug: Fruquintinib、Nivolumab、Sintilimab、Oxaliplatin、Teysuno、Capecitabine
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 58
- Registration Number
- NCT06158919
- Locations
- 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China
PD-1 Inhibitor Based Induction Chemotherapy Followed by De-escalation Protocols in OPSCC
Phase 2
Recruiting
- Conditions
- Oropharyngeal Cancer
- Interventions
- Procedure: Conventional treatmentProcedure: Toxicities reduced treatment
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT06156891
- Locations
- 🇨🇳
Eye & ENT Hospital of Fudan University, Shanghai, Shanghai, China
PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
Phase 2
Recruiting
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Combination Product: Anti-EGFR and PD-1 inhibitor arm
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 41
- Registration Number
- NCT06156878
- Locations
- 🇨🇳
Eye & ENT Hospital of Fudan University, Shanghai, Shanghai, China
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
Early Phase 1
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- Drug: mRNA tumor vaccines
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06156267
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 182
- Registration Number
- NCT06152978
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath